Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
Xultophy is liraglutide and insulin degludec.
To improve glycemic control in adults with Type II diabetes mellitus (Victoza).
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions (Saxenda).
Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
Xultophy is liraglutide and insulin degludec.
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of the cardiovascular safety of liraglutide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/28/2025